Avricore Health Beheer

Beheer criteriumcontroles 2/4

De CEO Avricore Health is Hector Bremner, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 321.44K, bestaande uit 67.2% salaris en 32.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.62% van de aandelen van het bedrijf, ter waarde CA$ 229.60K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 5.4 jaar.

Belangrijke informatie

Hector Bremner

Algemeen directeur

CA$321.4k

Totale compensatie

Percentage CEO-salaris	67.2%
Dienstverband CEO	5.1yrs
Eigendom CEO	1.6%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Hector Bremner's beloning veranderd ten opzichte van Avricore Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$3k
Mar 31 2024	n/a	n/a	-CA$341k
Dec 31 2023	CA$321k	CA$216k	-CA$701k
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$901k
Mar 31 2023	n/a	n/a	-CA$824k
Dec 31 2022	CA$261k	CA$168k	-CA$818k
Sep 30 2022	n/a	n/a	-CA$782k
Jun 30 2022	n/a	n/a	-CA$1m
Mar 31 2022	n/a	n/a	-CA$1m
Dec 31 2021	CA$258k	CA$150k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$2m
Dec 31 2020	CA$185k	CA$150k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$909k
Jun 30 2020	n/a	n/a	-CA$1m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	CA$78k	CA$76k	-CA$2m

Compensatie versus markt: De totale vergoeding ($USD 230.73K ) Hector } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 173.45K ).

Compensatie versus inkomsten: De vergoeding van Hector is gestegen terwijl het bedrijf verliesgevend is.

CEO

Hector Bremner (42 yo)

5.1yrs

Tenure

CA$321,442

Compensatie

Mr. Hector Bremner serves as Chief Executive Officer at Avricore Health Inc. since October 15, 2019 and has been its Director since April 2, 2020. He served as an Executive Vice-President of Branding, Stra...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hector Bremner	CEO & Director	5.1yrs	CA$321.44k	1.62% CA$ 229.6k
Kiriaki Smith	CFO & Corporate Secretary	5.3yrs	CA$167.95k	0.82% CA$ 115.4k
Rodger Seccombe	CTO & Director	3.6yrs	CA$321.44k	4.84% CA$ 683.3k
Will Seccombe	Communications Advisor	3.7yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AVCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hector Bremner	CEO & Director	4.6yrs	CA$321.44k	1.62% CA$ 229.6k
Rodger Seccombe	CTO & Director	3.9yrs	CA$321.44k	4.84% CA$ 683.3k
David Hall	Independent Chairman of the Board	8.8yrs	CA$81.43k	1.41% CA$ 199.9k
Robert Sindelar	Independent Director	6.7yrs	CA$53.78k	0.88% CA$ 123.9k
Alan Arnstein	Independent Director	7.6yrs	CA$53.78k	0.025% CA$ 3.5k
Sherif Guorgui	Member of Advisory Board	5.4yrs	geen gegevens	geen gegevens
Philippe Ugnat	Member of Advisory Board	5.2yrs	geen gegevens	geen gegevens
Ray Chepsiuk	Member of Advisory Board	5.8yrs	geen gegevens	geen gegevens
Mark Zhou	Member of Advisory Board	5.7yrs	geen gegevens	geen gegevens
David Huston	Member of Advisory Board	5.4yrs	geen gegevens	geen gegevens
David Noshad	Member of Advisory Board	5.1yrs	geen gegevens	geen gegevens
Sotiris Antoniou	Member of Advisory Board	5.1yrs	geen gegevens	geen gegevens

5.4yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AVCR wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Avricore Health Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CTO & Director recently sold CA$51k worth of stock

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

Avricore Health Inc. Announces Board Changes

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

High number of new directors

Recent updates

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

CTO & Director recently sold CA$51k worth of stock

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

New minor risk - Share price stability

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

New minor risk - Share price stability

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Independent Director exercised options to buy CA$80k worth of stock.

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

New 90-day high: CA$0.27

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

New 90-day high: CA$0.26

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd